Arcadia Stubs Toe In Nail Fungus Ad Challenge, Giving Advantice Foot In Door On Appeal
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
You may also be interested in...
Without study it conducted after first review, Advantice wouldn’t have changed NAD’s conclusion on firm’s claim its product “starts improving nail appearance in just 2 days.” Without Arcadia’s premature publication of recommendation following NAD’s first review, Advantice wouldn’t have second chance.
Three years ago, the Kerasal fungal nail brand brought a challenge to the National Advertising Division that decimated claims for competing Fungi-Nail products and got federal agencies involved. The shoe is now on the other foot, as the NAD agrees with Fungi-Nail that a slew of Kerasal claims should be discontinued.
New Jersey-based Arcadia Consumer Healthcare, Inc., succeeded in reopening a 2018 National Advertising Division case involving its ‘#1 Pharmacist Recommended’ claim for the Fungi-Nail line, but failed again to convince the NAD that survey findings justify the claim.